| scholarly article | Q13442814 |
| P50 | author | Paul Ridker | Q7153226 |
| Wolfgang Koenig | Q20172819 | ||
| P2860 | cites work | Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association | Q22241929 |
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q28214393 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
| Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial | Q34158442 | ||
| Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra | Q34189543 | ||
| Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial | Q34275827 | ||
| Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project | Q34534248 | ||
| C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis | Q35182277 | ||
| A randomized trial of rosuvastatin in the prevention of venous thromboembolism | Q37262627 | ||
| European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice | Q49154329 | ||
| Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program | Q79961696 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 75-83 | |
| P577 | publication date | 2010-10-22 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities | |
| P478 | volume | 32 |
| Q43601036 | Assessment of auditory processing disorder in children using an adaptive filtered speech test |
| Q38072595 | Between risk charts and imaging: how should we stratify cardiovascular risk in clinical practice? |
| Q35252544 | Estimating treatment effects for individual patients based on the results of randomised clinical trials |
| Q37956537 | Initiation of statin therapy: are there age limits? |
| Q35172886 | JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses |
| Q37901053 | Metabolic syndrome: nature, therapeutic solutions and options |
| Q33972551 | Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey |
| Q34636887 | Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease |
| Q36088110 | Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. |
| Q24187238 | Statins for primary prevention of venous thromboembolism |
| Q24204040 | Statins for primary prevention of venous thromboembolism |
| Q24201513 | Statins for the primary prevention of cardiovascular disease |
| Q38452600 | The relevance of biomarkers for personalised medicine |
| Q38680523 | The systematic coronary risk evaluation (SCORE) for the prevention of cardiovascular diseases. Does evidence exist for its effectiveness? A systematic review. |
| Q82085276 | What intervention trials don't tell us: the residual risk in primary prevention |
| Q82145730 | [Extrapolating the NNT jeopardises biostatistics and leads to immortality] |
Search more.